{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Overall response is defined as the number of participants achieving Complete Remission (CR) or Complete Remission without recovery of counts (CRi) CR is Normalization of the peripheral blood and bone marrow with \\</= to 5 % blasts with a granulocyte count of 1 x 10\\^9/L or greater and a platelet count of 100 x 10\\^9/L and complete resolution of all extramedullary disease. CRi is Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets \\< 100 x 10\\^9/L or neutrophils \\< 1 x 10\\^9/L).","groups":[{"description":"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nTrametinib: Given PO\n\nVenetoclax: Given PO","id":"OG000","title":"Cohort A (Newly Diagnosed AML Patients)"},{"description":"INDUCTION (CYCLE 1): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-28, and trametinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION (CYCLES 2-24): Patients receive azacitidine IV over 30-60 minutes or SC on days 1-7, venetoclax PO QD on days 1-21, and trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nTrametinib: Given PO\n\nVenetoclax: Given PO","id":"OG001","title":"Cohort B (Relapsed/Refractory AML or Higher-risk MDS or CMML Patients)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Of the five participants registered on Cohort A, three were evaluable. Of the sixteen participants registered on Cohort B, thirteen were evaluable.","reportingStatus":"POSTED","timeFrame":"Up to 2.5 years","title":"Participants With a Response","type":"PRIMARY","unitOfMeasure":"Participants"}